Jazz Pharmaceuticals has struck a deal to source two targeted cancer therapies from Redx Pharma. Redx will pocket $10 million upfront, with more to follow, in return for developing candidates against two targets on the Ras/Raf/MAP kinase (MAPK) pathway.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,